Stephens Remains Sidelined on Square (SQ) Following 3Q Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Square (SQ) PT Lowered to $100 at Buckingham Research
November 8, 2018 9:56 AM ESTBuckingham Research analyst Chris Brendler lowered the price target on Square (NYSE: SQ) to $100.00 (from $105.00) while maintaining a Buy rating.
... MoreSusquehanna Downgrades Square (SQ) to Neutral
November 8, 2018 7:06 AM ESTSusquehanna analyst James Friedman downgraded Square (NYSE: SQ) from Positive to Neutral with a price target of $77.00.
For an analyst ratings summary and ratings history on Square click here. For more ratings news on Square click here.
Shares of Square closed at $78.51 yesterday.
... MoreGoldman Expects Square (SQ) To Hold Its Gains
November 8, 2018 7:03 AM ESTGoldman Sachs analyst, James Schneider, reiterated his Buy rating on shares of Square (NYSE: SQ) and expects the share price to hold its gains heading into the print after 3Q18 adjusted revenue of $431mn came in above
Street (FactSet) at $414mn. Looking ahead, the company raised... More
Square's (SQ) Large Merchants And New Products Drove Revenue Growth Acceleration - Mizuho
November 8, 2018 6:35 AM ESTMizuho Securities analyst, Thomas McCrohan, reiterated his Buy rating on shares of Square (NYSE: SQ) and raised his price target to $95 from $90 after the company reported adjusted net revenue of $431.1 million (+68% YoY) that beat consensus of $414.1 million and guidance of $407-$412 million. Adjusted for acquisitions,... More
Square's (SQ) Triple Digit Subscription Growth Continues To Impress Stifel
November 8, 2018 6:27 AM ESTStifel analyst, Scott Devitt, reiterated his Buy rating on shares of Square (NYSE: SQ) after the company reported . revenue and adj. EBITDA forecasts which were both above the high end of guidance as revenue growth accelerated for the sixth consecutive quarter reaching 68% or 56% organic. Subscription and services revenue growth was the highlight... More
Square's (SQ) Beat And Raise Isn't Good Enough For BTIG, Reit Sell
November 8, 2018 6:11 AM ESTBTIG analyst, Mark Palmer, reiterated his Sell rating on shares of Square (NYSE: SQ) and believes the "good" report is not enough to meet lofty expectations to warrant the valuation premium.
The analyst stated "While the company reported beats versus consensus on net and... More
Square (SQ) Raises Guidance Taking EPS Up To 75c For 2019 At Deutsche Bank
November 8, 2018 6:05 AM ESTDeutsche Bank analyst, Bryan Keane, reiterated his Buy rating on shares of Square (NYSE: SQ) after organic rev growth accelerated to +56% Y/Y (from ~54% in 2Q18). FY19 guidance is for +40% adj. revenue growth and margin expansion similar to the FY18 outlook (~200bps... More
Popular stocks with increasing unusual: SQ CGC TLRY PFE
November 8, 2018 4:58 AM ESTPopular stocks with increasing unusual: SQ CGC TLRY PFE
... MoreSquare (SQ) PT Lowered to $92 at Piper Jaffray
November 8, 2018 4:28 AM ESTPiper Jaffray analyst Jason Deleeuw lowered the price target on Square (NYSE: SQ) to $92.00 (from $94.00) while maintaining a Neutral rating.
... MoreAfter-Hours Movers 11/7: (ALAM) (CVNA) (FOSL) Higher; (VYGR) (KRO) (WYNN) Lower (more...)
November 7, 2018 5:27 PM ESTToday's After-Hours Movers
Voyager Therapeutics, Inc. (NASDAQ: VYGR) 22.8% LOWER; announced positive longer-term results from the open-label, dose-escalating Phase 1b trial of VY-AADC demonstrating sustained improvements in patients motor function. Patients in the two highest dose cohorts (Cohorts 3 and 2) experienced mean improvements in diary on-time without troublesome dyskinesia (good ON time) of 1.7 hours per day at 18 months and 2.7 hours per day at two years, respectively.
Kronos Worldwide, Inc. (NYSE: KRO) 19.9% LOWER; reported net income of $32.6... More
Square (SQ) Tops Q3 EPS by 2c, Q4 Guidance Comes in Mixed
November 7, 2018 4:13 PM ESTSquare (NYSE: SQ) reported Q3 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $431 million versus the consensus estimate of $413.88 million.
GUIDANCE:
Square sees Q4 2018 EPS of $0.12-$0.13, versus the consensus of $0.15. Square sees Q4... More
Square (SQ) call put ratio 1.7 calls to 1 put with focus on November weekly 82.50 calls and puts into EPS
November 7, 2018 3:31 PM ESTSquare (NYSE: SQ) call put ratio 1.7 calls to 1 put with focus on November weekly 82.50 calls and puts into EPS
UPDATE: Citi Upgrades Square (SQ) to Buy
November 6, 2018 6:02 AM EST(Updated - November 6, 2018 7:09 AM EST)
(updated to add analyst comment)
Citi analyst Peter Christiansen upgraded Square (NYSE: SQ) from Neutral to Buy with a price target of $90.00 (from $67.00).
The analyst comments "We have no reason to believe Squares... More

